Compare Lupin Ltd with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs AJANTA PHARMA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN AJANTA PHARMA LUPIN/
AJANTA PHARMA
 
P/E (TTM) x -74.5 29.0 - View Chart
P/BV x 2.2 5.5 40.1% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 LUPIN   AJANTA PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-19
AJANTA PHARMA
Mar-19
LUPIN/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs9861,422 69.3%   
Low Rs720898 80.3%   
Sales per share (Unadj.) Rs369.5233.5 158.2%  
Earnings per share (Unadj.) Rs13.444.0 30.5%  
Cash flow per share (Unadj.) Rs37.452.2 71.7%  
Dividends per share (Unadj.) Rs09.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs303.7255.1 119.1%  
Shares outstanding (eoy) m452.4988.02 514.1%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x2.35.0 46.5%   
Avg P/E ratio x63.626.4 241.3%  
P/CF ratio (eoy) x22.822.2 102.6%  
Price / Book Value ratio x2.84.5 61.8%  
Dividend payout %020.5 0.0%   
Avg Mkt Cap Rs m386,064102,081 378.2%   
No. of employees `00017.76.8 260.1%   
Total wages/salary Rs m31,5134,307 731.7%   
Avg. sales/employee Rs Th9,453.83,022.6 312.8%   
Avg. wages/employee Rs Th1,782.0633.4 281.3%   
Avg. net profit/employee Rs Th343.0569.1 60.3%   
INCOME DATA
Net Sales Rs m167,18220,554 813.4%  
Other income Rs m3,640211 1,726.9%   
Total revenues Rs m170,82220,765 822.7%   
Gross profit Rs m28,8225,664 508.8%  
Depreciation Rs m10,850721 1,505.3%   
Interest Rs m3,07812 26,537.1%   
Profit before tax Rs m18,5345,143 360.4%   
Minority Interest Rs m-890-   
Prior Period Items Rs m380-   
Extraordinary Inc (Exp) Rs m-3,4000-   
Tax Rs m9,0171,273 708.3%   
Profit after tax Rs m6,0663,870 156.7%  
Gross profit margin %17.227.6 62.6%  
Effective tax rate %48.724.8 196.5%   
Net profit margin %3.618.8 19.3%  
BALANCE SHEET DATA
Current assets Rs m138,53611,812 1,172.8%   
Current liabilities Rs m61,2993,776 1,623.2%   
Net working cap to sales %46.239.1 118.2%  
Current ratio x2.33.1 72.3%  
Inventory Days Days8477 108.3%  
Debtors Days Days11282 137.8%  
Net fixed assets Rs m127,51614,398 885.6%   
Share capital Rs m905175 516.0%   
"Free" reserves Rs m136,51722,277 612.8%   
Net worth Rs m137,42222,452 612.1%   
Long term debt Rs m66,4177 1,006,321.2%   
Total assets Rs m279,49426,962 1,036.6%  
Interest coverage x7.0444.3 1.6%   
Debt to equity ratio x0.50 164,413.1%  
Sales to assets ratio x0.60.8 78.5%   
Return on assets %3.314.4 22.7%  
Return on equity %4.417.2 25.6%  
Return on capital %8.923.0 38.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m59,41410,682 556.2%   
Fx outflow Rs m22,2822,102 1,060.1%   
Net fx Rs m37,1328,580 432.8%   
CASH FLOW
From Operations Rs m16,6603,748 444.5%  
From Investments Rs m-32,825-2,228 1,473.3%  
From Financial Activity Rs m7,441-1,475 -504.6%  
Net Cashflow Rs m-8,72445 -19,300.2%  

Share Holding

Indian Promoters % 46.6 73.8 63.1%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 1.6 729.0%  
FIIs % 31.9 7.6 419.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 17.0 59.4%  
Shareholders   98,259 20,968 468.6%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  SANOFI INDIA  DR. DATSONS LABS  

Compare LUPIN With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Crashes 807 Points on Coronavirus Fears; Metal and Automobile Stocks Fall(Closing)

Indian share markets fell sharply today, tracking a global selloff as coronavirus cases spiked outside China.

Related Views on News

AJANTA PHARMA at 52 Week High; BSE 500 Index Down 0.9 % (Market Updates)

Feb 24, 2020 | Updated on Feb 24, 2020

AJANTA PHARMA share price has hit a 52-week high. It is presently trading at Rs 1,485. BSE 500 Index is down by 0.9% at 15,753. Within the BSE 500, AJANTA PHARMA (up 2.4%) and THOMAS COOK INDIA (up 13.2%) are among the top gainers, while top losers are AUROBINDO PHARMA and GAYATRI PROJECTS.

AJANTA PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 60.8% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

The Top 8 Trading Mistakes You Should Avoid(Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

These Rebirth of India Stocks Are Raring to Compete with Tesla(The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Feb 24, 2020 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS